TITLE

Role of Maintenance Therapy After Autologous Stem Cell Transplant for Multiple Myeloma: Lessons for Cancer Therapy

AUTHOR(S)
Kyle, Robert A.
PUB. DATE
May 2011
SOURCE
Mayo Clinic Proceedings;May2011, Vol. 86 Issue 5, p419
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers lessons for cancer therapy in association to the role of maintenance therapy after autologous stem cell transplant for multiple myeloma in the U.S. It notes that postoperative patients are subjected with lenalidomide and placebo for therapy to determine the progression-free survival (PFS). It discusses the adverse effects of lenalidomide as a complex immunomodulatory drug including cytopenia and fatigue. It highlights the cancer incidence of patients treated with the drug.
ACCESSION #
61207736

 

Related Articles

  • Multiple Myeloma: Turning a Once Deadly Disease Into a Manageable Disease.  // Ascribe Newswire: Medicine;6/14/2004, p99 

    Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it. Now...

  • The Role of Transplantation in Improving Patient Outcomes in Multiple Myeloma. Stadtmauer, Edward A. // Personalized Medicine in Oncology;Nov2013, Vol. 2 Issue 7, p397 

    The article presents questions and answers related to multiple myeloma including whether all transplant-eligible patients should receive early high-dose therapy and autologous stem cell transplantation (HDT/ASCT), whether high initial response rates seen with novel agents are translating into...

  • Pharmacologic Considerations in the Transplant Setting for Myeloma. Ganetsky, Alex // Personalized Medicine in Oncology;Nov2013, Vol. 2 Issue 7, p401 

    The article presents questions and answers related to multiple myeloma (MM) including the role of risk stratification in the selection of induction therapy for transplant-eligible patients, and the strategies that can be used to optimize stem-cell mobilization prior to transplant.

  • Myelosuppression Associated With Novel Therapies in Patients With Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board. Miceli, Teresa; Colson, Kathleen; Gavino, Maria; Lilleby, Kathy // Clinical Journal of Oncology Nursing;Jun2008 Supplement, Vol. 12, p13 

    Novel therapies for multiple myeloma include the immunomodulatory drugs lenalidomide and thalidomide and the proteasome inhibitor bortezomib, which have increased response rates and survival times. However, the agents can cause myelosuppression, which, if not managed effectively, can be life...

  • Multiple Myeloma: Turning a Once Deadly Disease Into a Manageable Disease.  // Ascribe Newswire: Health;6/11/2004, p103 

    Science is increasingly commuting the death sentence that is a diagnosis of multiple myeloma. A cancer of the plasma cells that primarily strikes the elderly, multiple myeloma has been deadly because patients have been unable to withstand the aggressive treatment necessary to combat it. Now...

  • Melphalan.  // Reactions Weekly;2/21/2009, Issue 1240, p30 

    The article presents cases of five patients who underwent haematopoietic stem cell transplantation for multiple myeloma and developed sever autologous graft-versus-host disease (GVHD) following intensive conditioning with melphalan. It outlines some of the symptoms experienced by the patients...

  • Palifermin.  // Reactions Weekly;7/21/2007, Issue 1161, p20 

    The article describes the case of a 45-year-old obese woman with multiple myeloma, who was undergoing chemotherapy with melphalan followed by autologous stem cell transplantation, who was noted to have impaired glucose tolerance. The patient developed a bilateral hyperpigmented hyperkeratotic...

  • Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection. Mya, D. H. T.; Han, S. T.; Linn, Y. C.; Hwang, W. Y. K.; Goh, Y. T.; Tan, D. C. L. // Annals of Oncology;Feb2012, Vol. 23 Issue 2, p421 

    Background: The purpose of the study is to analyse the prevalence of hepatitis B virus (HBV) infection and its incidence of reactivation among multiple myeloma (MM) patients treated in the era of novel therapy in an endemic Asian setting. Patients and methods: From 2000 to 2008, 273 patients...

  • The Impact of New Emerging Drugs in the Treatment of Multiple Myeloma: Is there Still a Role for PBSC Transplantation? Corso, Alessandro; Varettoni, Marzia // Current Stem Cell Research & Therapy;Jan2007, Vol. 2 Issue 1, p1 

    High-dose therapy with the rescue of autologous stem cells represents today the standard approach for multiple myeloma patients aged <65 years. Several studies, in fact, have demonstrated the superiority of high-dose therapy with respect to conventional chemotherapy in younger patients....

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics